Sixty Years of Placebo-Controlled Antipsychotic Drug Trials in Acute Schizophrenia: Systematic Review, Bayesian Meta-Analysis, and Meta-Regression of Efficacy Predictors.

@article{Leucht2017SixtyYO,
  title={Sixty Years of Placebo-Controlled Antipsychotic Drug Trials in Acute Schizophrenia: Systematic Review, Bayesian Meta-Analysis, and Meta-Regression of Efficacy Predictors.},
  author={Stefan Leucht and Claudia Leucht and Maximilian Huhn and Anna Chaimani and Dimitris Mavridis and Bartosz Helfer and Myrto Samara and Matteo Rabaioli and Susanne B{\"a}cher and Andrea Cipriani and John R. Geddes and Georgia Salanti and John M. Davis},
  journal={The American journal of psychiatry},
  year={2017},
  volume={174 10},
  pages={
          927-942
        }
}
OBJECTIVE Antipsychotic drug efficacy may have decreased over recent decades. The authors present a meta-analysis of all placebo-controlled trials in patients with acute exacerbations of schizophrenia, and they investigate which trial characteristics have changed over the years and which are moderators of drug-placebo efficacy differences. METHOD The search included multiple electronic databases. The outcomes were overall efficacy (primary outcome); responder and dropout rates; positive… 

Tables from this paper

Predictors of Placebo Response in Pharmacological Clinical Trials of Negative Symptoms in Schizophrenia: A Meta-regression Analysis
TLDR
The results suggest that some clinical trial design and operational factors affect the level of placebo response in such studies, thus highlighting the need for designs better suited to assess these outcomes.
Disconnection of drug-response and placebo-response in acute-phase antipsychotic drug trials on schizophrenia? Meta-regression analysis
TLDR
As individual moderators may have different impact on placebo-response and drug-response, it is important to consider also the specific factors influencing drug- response in order to fully understand the difference between antipsychotics and placebo.
The acute efficacy of antipsychotics in schizophrenia: a review of recent meta-analyses
TLDR
Key meta-analytic findings regarding antipsychotic efficacy in the acute treatment of schizophrenia are summarized, including clozapine in treatment-resistant patients and first-episode patients.
Antidepressive Effect of Antipsychotics in the Treatment of Schizophrenia: Meta-Regression Analysis of Randomized Placebo-Controlled Trials
TLDR
The antidepressive effect of antipsychotics was significantly correlated with improvement in other symptom domains, with the highest correlation observed for improvement in negative symptoms.
The Efficacy and Heterogeneity of Antipsychotic Response in Schizophrenia: A Meta-analysis
TLDR
Evidence is provided for a relatively homogeneous effect of antipsychotic treatment in improving symptoms of schizophrenia, contrary to the hypothesis that there is a subtype of antippsychotic non-responsive schizophrenia.
Placebo-controlled Pharmacological Trials in Child and Adolescents with Bipolar Disorder Manic Episode (BPD-ME): Systematic review, Meta-analysis and a Meta-regression on Placebo Response
TLDR
Modifying number of the sites or ramdomized sample size may limit placebo response and could improve the efficacy of RCT`s and enhance drugplacebo contrasts.
Evaluation of Differences in Individual Treatment Response in Schizophrenia Spectrum Disorders: A Meta-analysis.
TLDR
No evidence was found in RCTs that antipsychotic drugs increased the outcome variance, suggesting no personal element of response to treatment but instead indicating that the variance was slightly lower in the treatment group than in the control group, suggesting that the average treatment effect is a reasonable assumption for the individual patient.
...
...

References

SHOWING 1-10 OF 91 REFERENCES
Dropout rates in placebo-controlled and active-control clinical trials of antipsychotic drugs: a meta-analysis.
TLDR
Using a placebo-controlled design had a major effect on the dropout rates observed, and it is suggested that, in addition to the PCTs, studies with alternative designs need to be considered when evaluating an antipsychotic's clinical profile.
Meta-regression analysis of placebo response in antipsychotic trials, 1970-2010.
TLDR
This study identified important patient characteristics and trial design factors affecting the level of placebo response and hence the likelihood of detecting efficacy signals in randomized controlled trials.
Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis
Initial severity of schizophrenia and efficacy of antipsychotics: participant-level meta-analysis of 6 placebo-controlled studies.
TLDR
Benefits of antipsychotic drugs can be expected for the full spectrum of patients likely to be treated for acute schizophrenia and for highly symptomatic patients with predominantly negative symptoms, particularly at the mildest end of the spectrum.
How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials
TLDR
It is concluded that the drug versus placebo difference of SGA drugs and haloperidol in recent trials was moderate, and that there is much room for more efficacious compounds.
Placebo response in antipsychotic clinical trials: a meta-analysis.
TLDR
The average treatmentChange associated with placebo treatment in antipsychotic trials increased since 1960, while the change associated with medication treatment decreased, indicating that the average drug-placebo difference significantly decreased over time, with decreasing baseline severity and with increasing study duration.
Determinants of antipsychotic response in schizophrenia: implications for practice and future clinical trials.
TLDR
Proof-of-concept trials can be shorter and efficiency improved by including an even distribution of sexes and of patients with prominent symptomatology, thus reducing patient exposure to placebo and experimental treatments.
Feasibility of reducing the duration of placebo-controlled trials in schizophrenia research.
TLDR
Future antipsychotic trials could be shortened from 6-8 weeks to 3-4 weeks with a relatively low increase in sample size requirements, to reduce patient burden and ethical objections to prolonged administration of placebo and reduce potential bias due to high dropout rates in longer clinical trials.
Oral fluphenazine versus placebo for schizophrenia.
TLDR
There is evidence that oral fluphenazine, in the short term, increases a person's chances of experiencing extrapyramidal effects such as akathisia, but there is also evidence that fl uphenazine's global position as an effective treatment for psychoses is not threatened by the outcome of this review.
...
...